XML 16 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue
 6 Months Ended
Jun. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenue
Revenue
Revenue disaggregated by customer profile is as follows:
 
Three Months Ended
 
Six Months Ended
 
June 30, 2018
June 30, 2017
 
June 30, 2018
June 30, 2017
 
(in thousands)
 
(in thousands)
 
 
 
 

 
Top client
$
90,526

$
86,239

 
$
156,344

$
190,922

Clients 2-5
168,305

92,852

 
336,773

183,163

Clients 6-10
104,301

52,853

 
221,366

106,283

Clients 11-25
125,758

79,633

 
246,065

149,008

Other
152,720

119,446

 
301,187

233,601

 
 
 
 

 
Total
$
641,610

$
431,023

 
$
1,261,735

$
862,977

Trade accounts receivable, unbilled services and payments on account

Trade accounts receivables and unbilled revenue are as follows:
 
June 30, 2018

 
December 31, 2017

 
(in thousands)
Contract assets:
 
 
 
Billed services (accounts receivable)
$
412,933


$
388,431

Unbilled services (unbilled revenue)
274,501


268,509

Trade accounts receivable and unbilled revenue
687,434


656,940

Allowance for doubtful accounts
(8,361
)

(8,930
)
 
 
 
 
Trade accounts receivable and unbilled revenue, net
$
679,073


$
648,010


Unbilled services and payments on account were as follows:
(in thousands, except percentages)
June 30, 2018

 
December 31, 2017

 
$ Change
 
% Change
 
 
 
 
 
 
Unbilled services (unbilled revenue)
$
274,501

 
$
268,509

 
$
5,992

 
2.2
 %
Unearned revenue (payments on account)
(326,741
)
 
(298,992
)
 
(27,749
)
 
9.3
 %
 
 
 
 
 
 
 
 
Net balance
$
(52,240
)
 
$
(30,483
)
 
$
(21,757
)
 
(71.4
)%


Unbilled services as at June 30, 2018 increased by $6.0 million as compared to December 31, 2017. Adoption of ASC 606 as at January 1, 2018 resulted in a net reduction in unbilled revenue of $42 million. Unbilled services/revenue balances arise where invoicing or billing is based on the timing of agreed milestones related to service contracts for clinical research. Payments on account increased by $27.7 million over the same period resulting in a decrease of $21.8 million in the net balance of unbilled services and payments on account between December 31, 2017 and June 30, 2018. These fluctuations are primarily due to timing of payments and invoicing related to the Group's clinical trial management contracts.

The bad debt expense recognized on the Group's receivables and unbilled services was de minimis for the three and six months ended June 30, 2018.

As of June 30, 2018 approximately $5.0 billion of revenue is expected to be recognized in the future in respect of unrealized performance obligations. The Company expects to recognize revenue on approximately 40% of the unrealized performance obligation over the next 12 months, with the remainder recognized thereafter over the duration of the customer contracts.